European Lithium Ltd - Issue of Options
RNS Number : 1053K
European Lithium Limited
11 December 2018
 

European Lithium Ltd

("European Lithium", "EUR" or "the Company")

Issue of Options

European Lithium Limited (ASX:EUR, FRA:PF8, VSE:ELI, NEX:EUR) (the Company) advises that 11,250,000 options over ordinary shares have been granted to to the Directors of the company as set out below, representing approximately 2.05% of the Company's current issued share capital. Each option is exercisable at AU$0.15 on or before 31st May 2019.

 

Granted To

Options Granted

Exercise Price

Tony Sage, Non-Executive Chairman

2,500,000

AU$0.15

Stefan Mueller, Non-Executive Director

6,250,000

AU$0.15

Malcolm Day, Non Executive Director

2,500,000

AU$0.15

 

The Company also advises that 2,500,000 options over ordinary shares have been granted to Empire Capital Partners Pty Ltd (Empire), for services provided in establishing the Company's convertible note facility with Magna, representing approximately 0.46% of the Company's current issued share capital. Each option is exercisable at AU$0.20 on or before 11th December 2021.

This issue of options to Directors and Empire are as resolved at the Company's AGM held on 28th November 2018.

For announcements released on the ASX in relation to this please visit: https://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=EUR&timeframe=D&period=M6

- END -

 

Visit the Company's website to find out more about the advanced Wolfsberg Lithium Project located in Austria.

For further information please contact:

European Lithium Ltd

+61 861 819 792

Tony Sage

info@europeanlithium.com

 

 

NEX Corporate Adviser

+44 207 220 1666

James Joyce


James Sinclair-Ford




Tavistock (UK PR & IR Adviser)


Emily Fenton / Oliver Lamb

+44 207 920 3150

+44 778 855 4035

 

 


This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NEXGCBDDSUBBGIB ]]>